China Regenerative Medicine International Balance Sheet Health
Financial Health criteria checks 4/6
China Regenerative Medicine International has a total shareholder equity of HK$25.2M and total debt of HK$49.1M, which brings its debt-to-equity ratio to 194.9%. Its total assets and total liabilities are HK$135.7M and HK$110.5M respectively. China Regenerative Medicine International's EBIT is HK$6.1M making its interest coverage ratio -0.4. It has cash and short-term investments of HK$22.7M.
Key information
194.87%
Debt to equity ratio
HK$49.10m
Debt
| Interest coverage ratio | -0.4x |
| Cash | HK$22.70m |
| Equity | HK$25.20m |
| Total liabilities | HK$110.51m |
| Total assets | HK$135.71m |
Recent financial health updates
China Regenerative Medicine International (HKG:8158) Seems To Use Debt Quite Sensibly
May 15
These 4 Measures Indicate That China Regenerative Medicine International (HKG:8158) Is Using Debt Extensively
Sep 21Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
May 22Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
Apr 13Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Sep 22Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Nov 24Recent updates
China Regenerative Medicine International (HKG:8158) Seems To Use Debt Quite Sensibly
May 15Improved Revenues Required Before China Regenerative Medicine International Limited (HKG:8158) Stock's 26% Jump Looks Justified
Apr 08Little Excitement Around China Regenerative Medicine International Limited's (HKG:8158) Revenues As Shares Take 32% Pounding
Mar 05China Regenerative Medicine International Limited's (HKG:8158) Price Is Right But Growth Is Lacking After Shares Rocket 57%
Jan 04These 4 Measures Indicate That China Regenerative Medicine International (HKG:8158) Is Using Debt Extensively
Sep 21China Regenerative Medicine International Limited (HKG:8158) May Have Run Too Fast Too Soon With Recent 31% Price Plummet
Jun 11Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
May 22Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
Apr 13Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Sep 22Introducing China Regenerative Medicine International (HKG:8158), The Stock That Zoomed 142% In The Last Year
Mar 16What Is The Ownership Structure Like For China Regenerative Medicine International Limited (HKG:8158)?
Feb 08Trade Alert: The CEO & Executive Chairman Of China Regenerative Medicine International Limited (HKG:8158), Chuang Wang, Has Just Spent HK$55m Buying 428% More Shares
Dec 15
Don't Ignore The Fact That This Insider Just Sold Some Shares In China Regenerative Medicine International Limited (HKG:8158)
Nov 25Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Nov 24Financial Position Analysis
Short Term Liabilities: 8158's short term assets (HK$58.3M) do not cover its short term liabilities (HK$58.9M).
Long Term Liabilities: 8158's short term assets (HK$58.3M) exceed its long term liabilities (HK$51.6M).
Debt to Equity History and Analysis
Debt Level: 8158's net debt to equity ratio (104.8%) is considered high.
Reducing Debt: 8158's debt to equity ratio has reduced from 1488.5% to 194.9% over the past 5 years.
Debt Coverage: 8158's debt is well covered by operating cash flow (37.3%).
Interest Coverage: 8158 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/15 10:59 |
| End of Day Share Price | 2025/05/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Regenerative Medicine International Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.